229 related articles for article (PubMed ID: 24595456)
1. Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells.
Sztiller-Sikorska M; Koprowska K; Majchrzak K; Hartman M; Czyz M
PLoS One; 2014; 9(3):e90783. PubMed ID: 24595456
[TBL] [Abstract][Full Text] [Related]
2. Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres.
Czyz M; Koprowska K; Sztiller-Sikorska M
Cancer Biol Ther; 2013 Feb; 14(2):135-45. PubMed ID: 23192276
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative and pro-apoptotic activity of glycosidic derivatives of lawsone in melanoma cancer cell.
de Franca MNF; Isidório RG; Bonifacio JHO; Dos Santos EWP; Santos JF; Ottoni FM; de Lucca Junior W; Scher R; Alves RJ; Corrêa CB
BMC Cancer; 2021 Jun; 21(1):662. PubMed ID: 34078316
[TBL] [Abstract][Full Text] [Related]
4. ABCB5 is activated by MITF and β-catenin and is associated with melanoma differentiation.
Louphrasitthiphol P; Chauhan J; Goding CR
Pigment Cell Melanoma Res; 2020 Jan; 33(1):112-118. PubMed ID: 31595650
[TBL] [Abstract][Full Text] [Related]
5. Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment.
Sztiller-Sikorska M; Koprowska K; Jakubowska J; Zalesna I; Stasiak M; Duechler M; Czyz ME
Melanoma Res; 2012 Jun; 22(3):215-24. PubMed ID: 22495670
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic diversity of patient-derived melanoma populations in stem cell medium.
Sztiller-Sikorska M; Hartman ML; Talar B; Jakubowska J; Zalesna I; Czyz M
Lab Invest; 2015 Jun; 95(6):672-83. PubMed ID: 25867763
[TBL] [Abstract][Full Text] [Related]
7. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity.
Touil Y; Zuliani T; Wolowczuk I; Kuranda K; Prochazkova J; Andrieux J; Le Roy H; Mortier L; Vandomme J; Jouy N; Masselot B; Ségard P; Quesnel B; Formstecher P; Polakowska R
Stem Cells; 2013 Apr; 31(4):641-51. PubMed ID: 23355370
[TBL] [Abstract][Full Text] [Related]
9. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
10. Parthenolide enhances dacarbazine activity against melanoma cells.
Koprowska K; Hartman ML; Sztiller-Sikorska M; Czyz ME
Anticancer Drugs; 2013 Sep; 24(8):835-45. PubMed ID: 23797801
[TBL] [Abstract][Full Text] [Related]
11. The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.
Ahn A; Chatterjee A; Eccles MR
Mol Cancer Ther; 2017 Jun; 16(6):1002-1009. PubMed ID: 28576947
[TBL] [Abstract][Full Text] [Related]
12. Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease.
Travnickova J; Wojciechowska S; Khamseh A; Gautier P; Brown DV; Lefevre T; Brombin A; Ewing A; Capper A; Spitzer M; Dilshat R; Semple CA; Mathers ME; Lister JA; Steingrimsson E; Voet T; Ponting CP; Patton EE
Cancer Res; 2019 Nov; 79(22):5769-5784. PubMed ID: 31582381
[TBL] [Abstract][Full Text] [Related]
13. Natural Products and Cancer Stem Cells.
Marucci C; Fumagalli G; Calogero F; Silvani A; Christodoulou MS; Martinet N; Passarella D
Curr Pharm Des; 2015; 21(38):5547-57. PubMed ID: 26429713
[TBL] [Abstract][Full Text] [Related]
14. Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells.
Shidal C; Al-Rayyan N; Yaddanapudi K; Davis KR
Oncotarget; 2016 Dec; 7(51):84128-84141. PubMed ID: 27566591
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K
Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292
[TBL] [Abstract][Full Text] [Related]
16. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
17. Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death.
Mokhamatam RB; Sahoo BK; Manna SK
Apoptosis; 2016 Aug; 21(8):928-40. PubMed ID: 27325430
[TBL] [Abstract][Full Text] [Related]
18. CD133⁺ melanoma subpopulation acquired resistance to caffeic acid phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: significance for melanoma treatment.
El-Khattouti A; Sheehan NT; Monico J; Drummond HA; Haikel Y; Brodell RT; Megahed M; Hassan M
Cancer Lett; 2015 Feb; 357(1):83-104. PubMed ID: 25449786
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.
Tornin J; Martinez-Cruzado L; Santos L; Rodriguez A; Núñez LE; Oro P; Hermosilla MA; Allonca E; Fernández-García MT; Astudillo A; Suarez C; Morís F; Rodriguez R
Oncotarget; 2016 May; 7(21):30935-50. PubMed ID: 27105533
[TBL] [Abstract][Full Text] [Related]
20. Natural Compounds Targeting Cancer Stem Cells: A Promising Resource for Chemotherapy.
Das PK; Zahan T; Abdur Rakib M; Khanam JA; Pillai S; Islam F
Anticancer Agents Med Chem; 2019; 19(15):1796-1808. PubMed ID: 31272363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
